We are monitoring the impact of COVID-19 on Europe Gastroparesis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5073
Share on
Share on

Europe Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5073
Pages: 145

Europe Gastroparesis Drugs Market Size (2021 to 2026)

The Europe Gastroparesis Drugs market size is estimated to be worth USD 1.73 billion by 2026 from USD 1.37 billion in 2021, growing at a CAGR of 4.70% during the forecast period. It captures 25% of the global market.

The market for the Gastroparesis drugs market in Europe is majorly driven by an increase in the number of surgeries that lead to postsurgical gastroparesis and the growing number of people with diabetes. Also, the surge in demand for user-friendly drugs is likely to augment the market growth. In addition, the introduction of new drugs in the market for controlling symptoms like nausea is witnessing a significant demand over the forecast period. Furthermore, the availability of reimbursement for in-patient hospital stays in developed countries is expected to drive Europe Gastroparesis Drugs' growth over the forecast period. 

On the other hand, the Initiatives taken by the government and non-government organizations in the developed countries and advancing healthcare infrastructure in Germany, UK, France, and Italy are proving lucrative growth opportunities for the market players, expanding the market growth. Moreover, the growing geriatric population is more prone to various diseases such as diabetes; therefore, Y-O-Y growth in the diabetic population in Europe is augmenting the market growth. 

Also, increasing healthcare spending among the people and easy access to healthcare services in the region are further projected to uplift the market growth. Furthermore, over the forecast period, the European diabetic gastroparesis treatment market is expected to rise due to an increase in diabetic gastroparesis medicines to reduce symptoms such as nausea and vomiting. 

The idiopathic gastroparesis category had the most significant market share, which is likely to continue during the forecast period. It's a type of gastroparesis that happens for no apparent reason. Nausea, vomiting, early satiety, postprandial fullness, and upper abdominal pain are symptoms of this form of gastroparesis, with abdominal pain being one of the most frequent. Dietary changes, prokinetic medicines, antiemetic pharmacological treatment, and symptom modulators can assist with this disease.

However, adverse effects associated with gastroparesis medicines, the time-consuming regulatory procedure for drug approval, and complications in gastroparesis diagnosis are limiting the market's growth. However, non-prescription drugs to control the symptoms restrict diagnosis of stage 1 and stage 2 gastroparesis.

This research report on the Europe Gastroparesis Drugs market has been segmented and sub-segmented into the following categories:

By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections    

By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

By End User:

  • Hospitals 
  • Pharmacies            
  • Clinics      
  • E-commerce     

Geographically, the European market is a close second by market share. The UK captured the largest market share in the European market.

Europe held the second most share in the Gastroparesis Drugs Market over the forecast period, and it is likely to witness significant growth throughout the forecast period. Many companies are likely to benefit from the region since Germany and the United Kingdom have a high prevalence of diabetes, which leads to gastroparesis disease, which accounts for a large portion of the market. Market players can profit from initiatives to help with product approvals and labeling claims for diabetic gastroparesis therapies. Moreover, the enormous untapped market potential in emerging countries such as France, the United Kingdom, and Italy and the advancement of novel gastroparesis medicines present lucrative opportunities for market participants.

Over the forecast period, Germany dominated the gastroparesis drugs market. The factors such as an increase in the diabetic population, growth in the geriatric population, and the introduction of novel drugs to control symptoms such as nausea and vomiting propel the market growth.

On the other hand, the UK is likely to account significant share in the gastroparesis drugs market owing to the availability of advanced healthcare services and favorable reimbursement policies, and increasing investment and funding by the government. 

Similarly, the countries such as France, Spain, and Italy are projected to contribute to the European regional market growth. The demand for diabetic gastroparesis treatments has increased in the last decade in these countries, which is expected to accelerate the market growth.

KEY MARKET PLAYERS:

A few of the notable companies operating in the European Gastroparesis drugs market profiled in this report are Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Drug Class                  

                              5.1.1 Introduction           

                              5.1.2 Prokinetic Agents 

                              5.1.3 Antiemetic Agents

                              5.1.4 Botulinum Toxin Injections              

                              5.1.5  Y-o-Y Growth Analysis, By Drug Class          

                              5.1.6  Market Attractiveness Analysis, By Drug Class        

                              5.1.7  Market Share Analysis, By Drug Class         

               5.2 Disease Type                            

                              5.2.1 Introduction           

                              5.2.2 Diabetic Gastroparesis       

                              5.2.3 Idiopathic Gastroparesis    

                              5.2.4 Post-surgical Gastroparesis              

                              5.2.5 Others      

                              5.2.6 Y-o-Y Growth Analysis, By Disease Type      

                              5.2.7 Market Attractiveness Analysis, By Disease Type    

                              5.2.8 Market Share Analysis, By Disease Type     

               5.3 End User                     

                              5.3.1 Introduction           

                              5.3.2 Hospitals  

                              5.3.3 Pharmacies             

                              5.3.4 Clinics       

                              5.3.5 E-commerce          

                              5.3.6 Y-o-Y Growth Analysis, By End User             

                              5.3.7 Market Attractiveness Analysis, By End User            

                              5.3.8 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Drug Class

                                             6.1.3.3 By Disease Type

                                             6.1.3.4 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Drug Class

                                             6.1.4.3 By Disease Type

                                             6.1.4.4 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Drug Class

                                             6.1.5.3 By Disease Type

                                             6.1.5.4 By End User

               6.2 U.K                

               6.3 Spain                           

               6.4 Germany                     

               6.5 Italy                             

               6.6 France                         

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Allergan, Plc.                            

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)                      

               8.3 AstraZeneca Plc.                      

               8.4 Cadila Pharmaceuticals Ltd.                

               8.5 ETX Pharma, Inc                      

               8.6 Evoke Pharma                          

               8.7 GlaxoSmithKline Plc.                             

               8.8 Neurogastrx, Inc.                    

               8.9 Valeant Pharmaceuticals International, Inc.                 

               8.10 Theravance Biopharma                      

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  2. Europe Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  6. Europe Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  10. Europe Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  11. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe E-commerce Market, By Region, From 2021 to 2026 (USD Billion)
  15. U.K. Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  16. U.K. Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  17. U.K. Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  18. Germany Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  19. Germany Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  20. Germany Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  21. France Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  22. France Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  23. France Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  24. Italy Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  25. Italy Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  26. Italy Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  27. Spain Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  28. Spain Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  29. Spain Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample